肝素结合膨体聚四氟乙烯移植物在缺乏合适自体静脉时是腘下动脉血运重建的解决方案
单中心回顾性分析348条因慢性肢体威胁性缺血(CLTI)行腘下动脉旁路术的肢体,比较自体静脉移植(VEIN组)与肝素结合膨体聚四氟乙烯(HePTFE)移植(HePTFE组)的结局。作者认为自体静脉仍是金标准,HePTFE可作为缺乏自体静脉时的替代选择。
要点
- HePTFE组3年无大截肢率69% vs VEIN组87%,无截肢生存率37% vs 59%,均较低。
核心结论
- 自体静脉移植是治疗CLTI肢体的金标准,HePTFE移植物应被视为缺乏自体静脉时复杂腘下动脉血运重建的替代选择。
研究设计与样本
- 单中心回顾性分析因CLTI行腘下动脉旁路术的患者,分为自体静脉移植组(VEIN组)和HePTFE移植组(HePTFE组)。
- 共纳入348条肢体,其中VEIN组214条、HePTFE组134条,中位随访25个月。
主要发现
- HePTFE组大多数患者为男性(69%),中位年龄76岁(四分位距15)。
- HePTFE组59%的肢体伤口分级≥2级,其中46%感染;88%为GLASS III期。
临床怎么用
- 作者认为,自体静脉移植是治疗CLTI肢体的金标准。
- 作者认为,HePTFE移植物应被视为缺乏自体静脉时复杂腘下动脉血运重建的替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To analyze the outcomes of heparin-bonded expanded polytetrafluoroethylene (HePTFE) graft as an alternative conduit in infrapopliteal revascularization of chronic limb-threatening ischemia (CLTI) in the absence of an autologous vein conduit. METHODS: A single-center retrospective analysis of patients with CLTI submitted to infrapopliteal bypasses with autologous vein graft (VEIN group) or HePTFE graft (HePTFE group) was implemented. Primary end points were freedom from CLTI at 12 months and recurrence of CLTI at 3 years. Secondary end points included freedom from major amputation, amputation-free survival (AFS), survival, and primary (PP) and secondary patency (SP) rates at 3 years of follow-up. RESULTS: A total of 348 limbs submitted to infrapopliteal bypasses, 214 with venous graft and 134 with HePTFE graft, were followed-up for a median of 25 months. Most patients of the HePTFE group were male (69%), with a median age of 76 years (interquartile range [IQR] 15). Fifty-nine percent of the limbs of the HePTFE group had Wound grade ≥2, being 46% of them infected. Eighty-eight percent were GLASS stage III. Freedom from CLTI was not significantly different between HePTFE and VEIN groups (75% vs. 84%, adjusted hazard ratio [aHR] 0.88, confidence interval [CI] 0.66-1.18, P = 0.401). Recurrence of CLTI was higher in the HePTFE group (42% vs.18% at 3 years; aHR 2.82, CI 1.59-5.00, P < 0.001). The VEIN group achieved higher rates of freedom from major amputation (87% vs.69% at 3 years; aHR 2.21, CI 1.31-3.75, P = 0.003) and AFS (59% vs. 37% at 3 years; aHR 1.39, CI 1.02-1.88, P = 0.036), but no significance in survival (aHR 1.10, CI 0.72-1.66, P = 0.667). Patency rates were inferior in the HePTFE group, with 2-year PP and SP rates of 52% vs. 74%, and 76% vs. 90%, respectively (PP: aHR 1.70, CI 1.11-2.59, P = 0.014; SP: aHR 2.51, CI 1.42-4.42, P = 0.001). CONCLUSIONS: Infrapopliteal bypass with autologous vein graft is the gold standard to treat CLTI limbs. HePTFE graft should be regarded as an alternative for complex infrapopliteal revascularization when lacking an autologous vein conduct.
引用
- Soares TR, Cabral G, Costa T, et al. Heparin-Bonded Expanded Polytetrafluoroethylene Is a Solution for Infrapopliteal Revascularization in the Absence of an Adequate Autologous Vein Graft. Ann Vasc Surg. 2023. PMID: 37355019. doi:10.1016/j.avsg.2023.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。